Docoh
Loading...

PTGX Protagonist Therapeutics

News

Pro users get this 30m faster
What 10 Analyst Ratings Have To Say About Protagonist Therapeutics
13 Oct 21
Analyst Ratings
Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ:PTGX) within the last quarter:
10 Biggest Price Target Changes For Wednesday
13 Oct 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
MKM Partners raised the price target on Continental Resources, Inc. (NYSE: CLR) from $47 to $54. Continental Resources shares fell 1.3% to $53.03 in pre-market trading.
JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $60
13 Oct 21
News, Price Target, Analyst Ratings
JMP Securities analyst Gobind Singh maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $47 to $60.
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Oct 21
Movers
Gainers
Analyst Ratings For Protagonist Therapeutics
12 Oct 21
Analyst Ratings
Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ:PTGX) within the last quarter:
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021
12 Oct 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Oct. 12, 2021: RRD, XPO, NTRB, OCGN, ZNGA
12 Oct 21
Pre-Market Outlook
Today's 5 Stock Ideas: R. R. Donnelley (RRD) - Shares were up 25% Tuesday morning following a Bloomberg report that suggested Chatham has offered to buy the remainder of R. R. Donnelley for $7.50 per
10 Biggest Price Target Changes For Tuesday
12 Oct 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Evercore ISI Group raised Lear Corporation (NYSE: LEA) price target from $170 to $220. Lear shares fell 0.3% to close at $167.76 on Monday.
JP Morgan Upgrades Protagonist Therapeutics to Overweight, Announces $55 Price Target
12 Oct 21
News, Upgrades, Price Target, Analyst Ratings
JP Morgan analyst Anupam Rama upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Neutral to Overweight and announces $55 price target.
46 Biggest Movers From Yesterday
12 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
SVB Leerink Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $50
12 Oct 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Joseph Schwartz maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $35 to $50.
Mid-Afternoon Market Update: Dow Tumbles Over 100 Points; Flexion Therapeutics Shares Spike Higher
11 Oct 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Toward the end of trading Monday, the Dow traded down 0.37% to 34,617.17 while the NASDAQ fell 0.05% to 34,617.14. The S&P also fell, dropping 0.26% to 4,379.88.
12 Health Care Stocks Moving In Monday's Intraday Session
11 Oct 21
Intraday Update, Markets, Movers
Where Protagonist Therapeutics Stands With Analysts
11 Oct 21
Analyst Ratings
Within the last quarter, Protagonist Therapeutics (NASDAQ:PTGX) has observed the following analyst ratings:
Mid-Day Market Update: Crude Oil Surges Over 2%; Supernus Pharmaceuticals To Acquire Adamas Pharmaceuticals
11 Oct 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Midway through trading Monday, the Dow traded up 0.50% to 34,920.55 while the NASDAQ rose 0.50% to 34,920.55. The S&P also rose, gaining 0.44% to 4,410.73.
28 Stocks Moving In Monday's Mid-Day Session
11 Oct 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers
Northland Capital Markets Upgrades Protagonist Therapeutics to Outperform, Announces $40 Price Target
11 Oct 21
News, Upgrades, Price Target, Analyst Ratings
Northland Capital Markets analyst Tim Chiang upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Market Perform to Outperform and announces $40 price target.
Protagonist Shares Almost Double As FDA Lifts Clinical Hold On Rusfertide Program
11 Oct 21
Biotech, Long Ideas, News, Health Care, Small Cap, FDA, Movers, Trading Ideas, General
Benzinga Pro's Top 5 Stocks To Watch For Monday, Oct. 11, 2021: SOFI, PTGX, GTLB, PRPH, AVDL
11 Oct 21
Pre-Market Outlook
Today's 5 Stock Ideas: SoFi Technologies (SOFI) - Shares were up 4% following initiation of coverage by a Morgan Stanley analyst. The analyst set an Overweight rating (the equivalent of a buy) and a set a $25
12 Health Care Stocks Moving In Monday's Pre-Market Session
11 Oct 21
Pre-Market Outlook, Markets, Movers
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The market value of their outstanding shares is at $1.6 billion.

Press releases

Pro users get this 30m faster
Protagonist Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit
12 Oct 21
Press Releases
NEWARK, Calif., Oct. 12, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive
Thinking about buying stock in Protagonist Therapeutics, Flexion Therapeutics, Avadel Pharmaceuticals, US Well Services, or Magnolia Oil & Gas?
11 Oct 21
Opinion, Press Releases
NEW YORK, Oct. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PTGX, FLXN, AVDL, USWS, and MGY.
Protagonist Therapeutics Announces Removal of FDA Clinical Hold on the Rusfertide Clinical Development Program
11 Oct 21
Press Releases
NEWARK, Calif., Oct. 11, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that the U.S. Food and Drug Administration (FDA) has removed the
Protagonist Therapeutics Announces Data from Phase 2 Rusfertide Study in Hereditary Hemochromatosis Selected for Oral Presentation at the Annual AASLD Meeting
4 Oct 21
Press Releases
NEWARK, Calif., Oct. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that an abstract highlighting new results from its Phase 2 study
PROTAGONIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Protagonist on Behalf of Protagonist Stockholders and Encourages Investors to Contact the Firm
22 Sep 21
Press Releases
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) on behalf of
Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) Investors
22 Sep 21
News, Legal, Press Releases
RADNOR, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Protagonist Therapeutics, Inc. - PTGX
21 Sep 21
Press Releases
New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX). Such investors
Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program
17 Sep 21
Press Releases
NEWARK, Calif., Sept. 17, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the receipt of a verbal communication from the U.S. Food and
Protagonist Therapeutics Reports Granting of Inducement Awards
15 Sep 21
Press Releases
NEWARK, Calif., Sept. 15, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on September 15, 2021, it issued inducement awards to two recently hired employees in accordance with the
Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma
10 Aug 21
News, Contracts, Press Releases
NEWARK, Calif., Aug. 10, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced it has resolved its Collaboration Agreement dispute with Zealand
Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress
4 Aug 21
Earnings, Press Releases
NEWARK, Calif., Aug. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported its financial results for the second quarter ended June 30, 2021,
Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists
28 Jul 21
News, Contracts, Press Releases
NEWARK, Calif., July 28, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced its entry into an amended collaboration agreement (the